Results 41 to 50 of about 2,024 (91)

Remdesivir and its antiviral activity against COVID-19: A systematic review

Clinical Epidemiology and Global Health, 2021
Background: The aim of this study was to summarize the antiviral activities of remdesivir against SARS-CoV-2, the causative agent of COVID-19. Methods: Available publications were systematically explored on some databases and gray literature was examined.
Andri Frediansyah, Firzan Nainu, Kuldeep Dhama, Mudatsir Mudatsir, Harapan Harapan   +4 more
doaj   +1 more source

Treatment effect of remdesivir on the mortality of hospitalised COVID-19 patients in Switzerland across different patient groups: a tree-based model analysis

Swiss Medical Weekly, 2023
AIMS OF THE STUDY: Remdesivir has shown benefits against COVID-19. However, it remains unclear whether, to what extent, and among whom remdesivir can reduce COVID-19-related mortality. We explored whether the treatment response to remdesivir differed by
Janne Estill, Plamenna Venkova-Marchevska, Huldrych F. Günthard, Sara Botero-Mesa, Amaury Thiabaud, Maroussia Roelens, Laure Vancauwenberghe, Lauro Damonti, Ulrich Heininger, Anne Iten, Peter W. Schreiber, Rami Sommerstein, Sarah Tschudin-Sutter, Nicolas Troillet, Danielle Vuichard-Gysin, Andreas Widmer, Torsten Hothorn, Olivia Keiser   +17 more
doaj   +1 more source

Safety and effectiveness of remdesivir for the treatment of COVID-19 patients with end-stage renal disease: A retrospective cohort study

Journal of Microbiology, Immunology and Infection
Background: Remdesivir has been used to treat severe coronavirus 2019 (COVID-19); however, its safety and effectiveness in patients remain unclear. This study aimed to investigate the safety and effectiveness of remdesivir in patients with COVID-19 with ...
Yan-Bo Huang, Chip-Jin Ng, Cheng-Hsun Chiu, Chung-Hsien Chaou, Shi-Ying Gao, Shou-Yen Chen   +5 more
doaj   +1 more source

The use of convalescent plasma therapy and remdesivir in the successful management of a critically ill obstetric patient with novel coronavirus 2019 infection: A case report

Case Reports in Women's Health, 2020
Summary: Remdesivir is a novel therapeutic with known activity against SARS CoV-2 and related coronaviruses. Remdesivir, as well as convalescent plasma therapy, are currently under investigation as potential therapies for patients with Coronavirus ...
Jonathon Anderson, Jordan Schauer, Suzanne Bryant, Cornelia R. Graves   +3 more
doaj   +1 more source

Acute pancreatitis or severe increase in pancreatic enzyme levels following remdesivir administration in COVID-19 patients: an observational study

Scientific Reports, 2022
Remdesivir has been shown to reduce recovery time and mortality among patients with coronavirus disease 2019 (COVID-19). However, data regarding the efficacy and safety of remdesivir use are limited in Japan.
Kazuhito Miyazaki, Yukihiro Yoshimura, Nobuyuki Miyata, Hiroaki Sasaki, Aya Shiba, Masaharu Aga, Yusuke Hamakawa, Yuri Taniguchi, Yuki Misumi, Yoko Agemi, Tsuneo Shimokawa, Hiroaki Okamoto, Natsuo Tachikawa   +12 more
doaj   +1 more source

Renal Clearable Luminogenic Reporter for Ultrasensitive Influenza Virus Imaging and Efficient Antiviral Therapies Monitoring in Living Mice

Advanced Science, EarlyView.
A viral luminogenic reporter with chemiluminescence/fluorescence dual‐response and efficient renal clearance was developed for non‐invasive imaging and urinalysis of H1N1 virus protease, allowing for remote detection of H1N1 virus infections and monitoring of antiviral therapeutic efficacy in living mice.
Bankang Ruan, Chudan Liang, Meilin Hu, Weiping Xu, Jingjing Che, Jun Qian, Bingcai Jiang, Linna Liu, Xiancai Ma, Jiaguo Huang   +9 more
wiley   +1 more source

Remdesivir-bisPropionate, a better derivative of remdesivir against SARS-CoV-2: Comparison of in vitro and in vivo PK/PD Study as well as its therapeutic potential.

PLoS ONE
FDA approved remdesivir, which was though very effective against SARS-corona virus in cell culture system but in human its efficacy was below 10%, as reported. The main reasons are due to the poor stability of remdesivir in presence plasma.
Ashok Chakraborty, Anil Diwan, Vijetha Chiniga, Vinod Arora, Yogesh Thakur, Jayant Tatake, Rajesh Pandey, Preetam Holkar, Neelam Holkar   +8 more
doaj   +1 more source

The Safe Administration of Remdesivir in a Patient with Acute Kidney Injury Requiring Hemodialysis

Case Reports in Infectious Diseases, 2020
Remdesivir is a nucleoside analog prodrug with broad-spectrum antiviral activity, including against coronaviruses. This has prioritized the inclusion of remdesivir in coronavirus disease 2019 (COVID-19) clinical trials.
Vincent Peyko, Helena Ladd, Anthony Cutrona   +2 more
doaj   +1 more source

Recent Advances in Virus–Host Interactions, Antiviral Bioactive Compounds, and Breeding for Disease Resistance of Porcine Epidemic Diarrhea Virus

Animal Research and One Health, EarlyView.
Basic research on the PEDV infection cycle and virus–host interactions advances the development of anti‐PEDV drugs and disease‐resistant breeding and helps strengthen disease prevention and control while reducing economic losses in the swine industry.
Heyong Wu, Aosi Qi, Shuyu Zhong, Haozhen Du, Shimeng Guo, Hongsheng Ouyang, Hongming Yuan, Daxin Pang, Zicong Xie   +8 more
wiley   +1 more source

Remdesivir administration for Japanese COVID-19 patients undergoing maintenance hemodialysis: a retrospective observation with six case reports

Renal Replacement Therapy, 2022
Background The mortality rate of novel coronaviral disease (COVID-19) patients undergoing dialysis is considerably higher than that of patients with normal kidney function.
Jun Ito, Moritsugu Kimura, Tomoyuki Toya, Konomi Isozumi, Atsuro Kawaji, Yudai Isozaki, Masafumi Fukagawa   +6 more
doaj   +1 more source